Loading stock data…
argenx SE (ARGX)
$1011.78-21.37 (-2.07%)
Market OpenUpdated 10:01 AM EDT
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
argenx SE in the Healthcare sector is trading at $1,033.15 with a market capitalization of $54.0B. Wall Street consensus targets $1,179.74 (23 analysts), implying a +14.2% move over the next 12 months. The stock is currently near its 52-week high of $1,072.75, remaining 22.3% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +14.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Total Revenue | $947.96M↓ | $1.13B↓ | $1.29B↓ | $1.30B↓ | $1.51B |
| Gross Profit | $837.21M↓ | $1.02B↓ | $1.14B↓ | $1.18B↓ | $1.37B |
| Operating Income | $203.84M↓ | $349.97M↓ | $359.56M↓ | $394.00M↓ | $494.00M |
| Net Income | $245.36M↓ | $344.26M↓ | $532.95M↑ | $366.00M↓ | $472.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and imm...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$53.98B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
33.06
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.04
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
20.38%
Volume
Today's trading volume
28,085
Recent News
Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated?
This biotech innovator could be in only the early chapters of its success story.
A single drug made Argenx one of the most valuable biotechs in Europe. Its new CEO is ready for the next act.
Under its new chief, Karen Massey, Argenx is positioning its blockbuster Vyvgart to become the Keytruda of the autoimmune disease space.
argenx (ENXTBR:ARGX) Stock Looks Rich Despite Its 210% Five Year Run
Argenx stock has delivered very strong gains over the past five years, yet current valuation checks suggest investors are paying a premium rather than buying into an obvious bargain. A 209.7% return over 5 years points to a stock where expectations have risen sharply and pricing now embeds a lot of optimism. Positive Phase 3 data for Vyvgart Hytrulo in autoimmune myositis can support high growth expectations, while execution and clinical risk around expanding the immunology pipeline may...
argenx (ENXTBR:ARGX) Just Gave Investors Something To Think About
argenx (ENXTBR:ARGX) is back in focus after reporting positive topline results from the ALKIVIA Phase 3 trial of VYVGART Hytrulo in autoimmune myositis, a rare muscle disease with limited targeted treatment options. argenx shares have reacted strongly around these developments, with a 30 day share price return of 17.54% and a 90 day share price return of 26.80%. The 1 year total shareholder return of 50.58% and 5 year total shareholder return of 209.69% suggest that momentum has been building...
Argenx (ENXTBR:ARGX) Completes Forte Biosciences Acquisition
argenx (ENXTBR:ARGX) has completed its acquisition of Forte Biosciences, adding antibody candidate FB102 to its immunology pipeline. The transaction supports argenx's Vision 2030 plan to broaden its presence in autoimmune disease treatment. FB102 is expected to be integrated into argenx's existing research and development programs focused on immunology. For readers who want more ideas in advanced immunology and related technologies, the next step is to explore 134 healthcare AI...